Evotec Crescita futura
Criteri Future verificati 3/6
Evotec prevede che gli utili e i ricavi cresceranno rispettivamente di 72.7% e 6.6% all'anno. Si prevede che l'EPS crescerà di 75.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 7.3% in 3 anni.
Informazioni chiave
72.7%
Tasso di crescita degli utili
75.87%
Tasso di crescita dell'EPS
| Life Sciences crescita degli utili | 20.2% |
| Tasso di crescita dei ricavi | 6.6% |
| Rendimento futuro del capitale proprio | 7.26% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 11 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 23
EVT: Future Milestone And Royalty Stream Will Support Earnings Upside
Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).
Aggiornamento della narrazione • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).
Aggiornamento della narrazione • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Aggiornamento della narrazione • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).Aggiornamento della narrazione • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.Aggiornamento della narrazione • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.Aggiornamento della narrazione • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.Aggiornamento della narrazione • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).Aggiornamento della narrazione • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.Aggiornamento della narrazione • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.Aggiornamento della narrazione • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.Aggiornamento della narrazione • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Aggiornamento della narrazione • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
Nuova narrazione • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Articolo di analisi • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...Articolo di analisi • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Articolo di analisi • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Articolo di analisi • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...Articolo di analisi • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Apr 10
Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...Articolo di analisi • Mar 05
These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jan 09
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price
With a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in Germany, you could be...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 897 | 45 | 31 | 138 | 7 |
| 12/31/2027 | 818 | -30 | -41 | 67 | 10 |
| 12/31/2026 | 738 | -125 | -143 | -8 | 8 |
| 3/31/2026 | 745 | -194 | -53 | 19 | N/A |
| 12/31/2025 | 788 | -104 | -92 | -9 | N/A |
| 9/30/2025 | 756 | -159 | -91 | 1 | N/A |
| 6/30/2025 | 777 | -156 | 12 | 112 | N/A |
| 3/31/2025 | 788 | -207 | -76 | 35 | N/A |
| 12/31/2024 | 797 | -196 | -114 | 18 | N/A |
| 9/30/2024 | 777 | -171 | -209 | -36 | N/A |
| 6/30/2024 | 788 | -171 | -246 | -55 | N/A |
| 3/31/2024 | 777 | -91 | -228 | -12 | N/A |
| 12/31/2023 | 781 | -84 | -180 | 36 | N/A |
| 9/30/2023 | 821 | -95 | -188 | -14 | N/A |
| 6/30/2023 | 798 | -103 | -246 | -42 | N/A |
| 3/31/2023 | 800 | -116 | -39 | 143 | N/A |
| 12/31/2022 | 751 | -176 | 24 | 206 | N/A |
| 9/30/2022 | 698 | -180 | 121 | 297 | N/A |
| 6/30/2022 | 684 | 2 | 194 | 322 | N/A |
| 3/31/2022 | 650 | 90 | 58 | 183 | N/A |
| 12/31/2021 | 618 | 216 | 3 | 122 | N/A |
| 9/30/2021 | 571 | 247 | -58 | 86 | N/A |
| 6/30/2021 | 541 | 112 | -50 | 93 | N/A |
| 3/31/2021 | 515 | 42 | -99 | 20 | N/A |
| 12/31/2020 | 501 | 6 | -54 | 45 | N/A |
| 9/30/2020 | 485 | 14 | -4 | 62 | N/A |
| 6/30/2020 | 470 | 35 | 0 | 46 | N/A |
| 3/31/2020 | 462 | 42 | 43 | 82 | N/A |
| 12/31/2019 | 446 | 38 | N/A | 42 | N/A |
| 9/30/2019 | 419 | 61 | N/A | 29 | N/A |
| 6/30/2019 | 404 | 77 | N/A | 74 | N/A |
| 3/31/2019 | 398 | 94 | N/A | 139 | N/A |
| 12/31/2018 | 375 | 84 | N/A | 156 | N/A |
| 9/30/2018 | 370 | 63 | N/A | 135 | N/A |
| 6/30/2018 | 338 | 31 | N/A | 80 | N/A |
| 3/31/2018 | 294 | 20 | N/A | 19 | N/A |
| 12/31/2017 | 264 | 23 | N/A | 11 | N/A |
| 9/30/2017 | 215 | 28 | N/A | 64 | N/A |
| 6/30/2017 | 193 | 35 | N/A | 73 | N/A |
| 3/31/2017 | 178 | 36 | N/A | 74 | N/A |
| 12/31/2016 | 165 | 28 | N/A | 67 | N/A |
| 9/30/2016 | 160 | 18 | N/A | 5 | N/A |
| 6/30/2016 | 148 | 6 | N/A | -6 | N/A |
| 3/31/2016 | 144 | 17 | N/A | -2 | N/A |
| 12/31/2015 | 128 | 17 | N/A | 16 | N/A |
| 9/30/2015 | 119 | 12 | N/A | 19 | N/A |
| 6/30/2015 | 104 | 11 | N/A | 23 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che EVT diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 1.9% ).
Guadagni vs Mercato: Si prevede che EVT diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede EVT diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di EVT ( 6.6% all'anno) crescerà più lentamente rispetto al mercato German ( 6.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di EVT ( 6.6% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di EVT sarà basso tra 3 anni ( 7.3 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/25 05:28 |
| Prezzo dell'azione a fine giornata | 2026/05/25 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Evotec SE è coperta da 23 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |